Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Biotech Investing
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines Biotech Investing
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 Biotech Investing
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ for Breast Cancer Biotech Investing
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis Biotech Investing
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 Biotech Investing
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder Biotech Investing
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress Biotech Investing
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis Biotech Investing
